Wafik El-Deiry Appointed Interim Director of the Penn State Hershey Cancer Institute

Wafik El-Deiry, M.D., Ph.D., FACP has been appointed the new interim director of the Penn State Hershey Cancer Institute, effective August 1, 2013. Dr. El-Deiry joined the faculty in 2010 as Professor of Medicine, Division Chief of Hematology/Oncology, and Associate Director for Translational Research for the Cancer Institute.  He also holds the Rose Dunlap Division Chair in Hematology/Oncology. Prior to joining Penn State Hershey, Dr. El-Deiry held a faculty appointment at the University of Pennsylvania, where he was a Howard Hughes Medical Institute Investigator from 1995 - 2004. He was named an American Cancer Society Research Professor in January, 2009. 

Click here to see a letter from the interim director.

About Us

The region’s only comprehensive cancer center, with access to internationally recognized cancer specialists and scientists delivering a multidisciplinary approach to cancer care, patient friendly facilities, and up-to-date medical technology. First in the region to offer RapidArc™ radiotherapy technology, a breakthrough in radiation treatment.

Catchment area includes 27 counties, many of them medically underserved. The Cancer Institute is a regional coordinator for the 13-county South Central Pennsylvania Cancer Education Network as selected by the Pennsylvania Department of Health. The Institute provides cancer screening to medically underserved, at-risk individuals; increases cancer knowledge and awareness of health intervention participants; and facilitates community changes that support a healthy environment.

Physicians and researchers are at the forefront of personalized cancer care to prevent and treat cancer with as few side  effects as possible, including personalized risk assessment and counseling, genetic and technological screening for cancer, personalized monitoring and dosing of chemotherapy. New drugs have been discovered and are being developed for clinical testing against the most difficult-to-treat, aggressive, and resistant cancers. Unique clinical trials are available for patients with either early stage or advanced cancer.

A Blue Distinction Center for Complex and Rare Cancers by Highmark Blue Shield, which designates the institute as a facility within Highmark’s service area that offers comprehensive inpatient cancer care programs for adults delivered by multidisciplinary teams with subspecialty training, and distinguished clinical expertise in treating complex and rare subtypes of cancer.